Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy

• Weixian Hu

Affiliations

Weixian Hu

Department of General Surgery Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou China